Merck Provides Update on REVEAL Outcomes Study

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck remains blinded to the actual results of this analysis and to other REVEAL safety and efficacy data. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News anacetrapib Merck MRK MSD NYSE:MRK REVEAL Source Type: news

Related Links:

CONCLUSIONS: Perceived devaluation was extremely prevalent among street-involved youth in our sample. We also observed that youth most in need of health and social services were significantly more likely to report high levels of perceived devaluation which may result in a reluctance to seek out key services and supports. These findings highlight the need to implement stigma reduction interventions for vulnerable youth in this setting. PMID: 30526206 [PubMed - as supplied by publisher]
Source: Substance Use and Misuse - Category: Addiction Tags: Subst Use Misuse Source Type: research
Conclusion/importance: This work is significant in expanding the populations thought to be impacted by and understanding social disparities related to SC use. Further investigation is needed to assess the relationship between concomitant use of SC and other drug, particularly opiates. This may suggest that the sequelae of one drug may enhance or alleviate the effects of the other. PMID: 30526203 [PubMed - as supplied by publisher]
Source: Substance Use and Misuse - Category: Addiction Tags: Subst Use Misuse Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Articles Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Editorial Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Review article Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Review article Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Review article Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Review article Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Review article Source Type: research
Source: Current Psychiatry Reviews - Category: Psychiatry Authors: Tags: Review article Source Type: research
More News: Merck | Pharmaceuticals | Study